Literature DB >> 12871078

Anti-epidermal growth factor receptor strategies to enhance radiation action.

G Lammering1.   

Abstract

The epidermal growth factor receptor (EGFR) has emerged as a central molecular target for modulation in cancer therapeutics, since EGFR signaling affects many factors that in turn promote tumor growth, progression and metastasis. In addition, radiobiological investigations have also defined a critical role for EGFR in mediating cytoprotective and pro-proliferative responses in human cancer cells after ionizing radiation, that contribute at least in part to accelerated tumor cell repopulation. This led to the additional development of EGFR as a target to enhance radiation efficacy. Several anti-EGFR strategies have been put forth demonstrating a favorable biological interaction between EGFR blockade and radiation. However, further preclinical investigations are necessary to better explore mechanisms of action and efficacy of combined treatment modalities. Although some of the anti-EGFR approaches have already reached clinical testing in combination with radiation, it is still too early to establish a clinical proof for the ultimate role of EGFR inhibition in combination with radiation. This article focuses primarily on anti-EGFR approaches to modulate radiation response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871078     DOI: 10.2174/1568011033482323

Source DB:  PubMed          Journal:  Curr Med Chem Anticancer Agents        ISSN: 1568-0118


  4 in total

1.  Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

Authors:  Jidong Hong; Yuping Peng; Yuping Liao; Wuzhong Jiang; Rui Wei; Lei Huo; Zaide Han; Chaojun Duan; Meizuo Zhong
Journal:  Exp Ther Med       Date:  2012-04-19       Impact factor: 2.447

2.  The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro.

Authors:  Amelie Rübel; René Handrick; Lars H Lindner; Matthias Steiger; Hansjörg Eibl; Wilfried Budach; Claus Belka; Verena Jendrossek
Journal:  Radiat Oncol       Date:  2006-03-29       Impact factor: 3.481

3.  Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.

Authors:  U Ganswindt; W Budach; V Jendrossek; G Becker; M Bamberg; C Belka
Journal:  Radiat Oncol       Date:  2006-04-10       Impact factor: 3.481

4.  New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity.

Authors:  Aurélie Henry; Marie-Julie Nokin; Natacha Leroi; François Lallemand; Jérémy Lambert; Nicolas Goffart; Patrick Roncarati; Elettra Bianchi; Paul Peixoto; Arnaud Blomme; Andrei Turtoi; Olivier Peulen; Yvette Habraken; Félix Scholtes; Philippe Martinive; Philippe Delvenne; Bernard Rogister; Vincent Castronovo; Akeila Bellahcène
Journal:  Oncotarget       Date:  2016-09-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.